OncoMaster Unveils AI Anti-Cancer Predictive Tech in Abu Dhabi, Steps Up Middle East Push

Precision medicine innovation company Oncomaster showcased its next-generation AI technology at the 'MAKE IT IN THE EMIRATES Forum 2025,' held in Abu Dhabi, UAE, the heart of the Middle East, marking its presence on the global stage. On May 20th, at this prestigious event, Oncomaster unveiled 'OCM-002,' an AI-based immunotherapy response prediction technology, drawing attention as a groundbreaking solution to tackle the challenge of low immunotherapy response rates, currently stagnant at around 30%. This forum, hosted by the UAE Ministry of Industry and Advanced Technology (MOIAT), is the Middle East's largest industry and innovation expo, gathering global startups with technologies set to lead future industries such as AI, precision medicine, and advanced manufacturing. Here, Oncomaster detailed the principles of its unique AI algorithm 'OCM-002,' which integrates and analyzes NGS genome-based multi-omics and vast clinical data. This technology is expected to play a crucial role in predicting how patients will respond to specific immunotherapies before treatment begins, thereby reducing unnecessary treatments and side effects, and establishing optimal personalized treatment strategies. CEO Jang Woo-young pointed out the reality that "despite immunotherapy bringing revolutionary changes to cancer treatment, many patients are not experiencing practical effects," emphasizing that "Oncomaster's AI technology will significantly contribute to shifting the paradigm of precision medicine in the Middle East by proposing the most effective treatment methods for individual patients." Starting with this forum, Oncomaster plans to establish cooperation systems with major hospitals and medical institutions in the Middle East and actively pursue joint research for OCM-002's clinical validation and local commercialization. The ambition is to provide personalized treatment strategies tailored to Middle Eastern patients through these efforts. Beyond predicting immunotherapy responses, Oncomaster is also accelerating the development of chemotherapy response prediction models. Ultimately, it is expanding its business scope across the board through the development of Clinical Decision Support Systems (CDSS), the discovery of innovative biomarkers, and strategic joint research with global pharmaceutical companies. Oncomaster's progress is noteworthy, having been selected in April for the Ministry of SMEs and Startups' 'Super Gap Startup 1000+' program, further accelerating the advancement of its AI precision medicine solutions as a national core strategic technology.